Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Biotechnology2.50%-0.59 ppLife Sciences Tools & Services1.81%+0.27 ppHealth Care Services0.93%+0.25 ppHealth Care Equipment3.19%+0.21 ppHealth Care Distributors0.35%-0.15 ppManaged Health Care1.93%-0.15 ppPharmaceuticals5.74%+0.14 ppHealth Care Facilities0.24%+0.04 ppHealth Care Supplies0.16%+0.02 ppHealth Care Technology0.00%+0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.50%
Industry change · 12M
-0.59 pp
Biotechnology · contribution
-0.587 pp
Company participation
86%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Apr 2019 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| AbbVie → ABBV | United States | $117.1bn | 0.652% | +0.254 pp | -0.290 pp | -13.9% | Yes |
| Gilead Sciences → GILD | United States | $83.0bn | 0.462% | +0.164 pp | -0.119 pp | -6.9% | Yes |
| Biogen → BIIB | United States | $44.4bn | 0.248% | +0.026 pp | -0.107 pp | -16.2% | No |
| Amgen → AMGN | United States | $111.6bn | 0.622% | +0.229 pp | -0.088 pp | +5.8% | Yes |
| Incyte → INCY | United States | $16.5bn | 0.092% | +0.035 pp | +0.011 pp | +24.0% | Yes |
| Regeneron Pharmaceuticals → REGN | United States | $32.2bn | 0.180% | +0.047 pp | +0.004 pp | +13.0% | Yes |
| Vertex Pharmaceuticals → VRTX | United States | $43.2bn | 0.241% | +0.080 pp | +0.001 pp | +10.3% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.